Co-Diagnostics Announces Reverse Stock Split
الأصول والمواضيع المتأثرة
لماذا يهم
التحليل معروض بالإنجليزية · الترجمة العربية قيد الإعداد
Co-Diagnostics, Inc. has announced a 1-for-30 reverse stock split to become effective on January 2, 2026, which may lead to increased stock price and reduced share count, potentially improving the company's market appearance.
نبرة المقال
التأثير المتوقع على السوق
Market impact analysis based on bullish sentiment with 80% confidence.
مسار الأدلة
الأدلة
مصدر التحليل بالذكاء الاصطناعي
المعرّفات التقنية
- وسم المزوّد
- groq-llama-3.1-8b-instant
- إصدار التحليل
- groq-llama-3.1-8b-instant
- معرّف المقال
- 27303
المصدر الأصلي
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to effect a reverse stock split of its common stock at a ratio of 1-for-30 shares. The reverse stock split will become effective at 12:01 a.m. ET on Friday, January 2, 2026. Co-Dx's common stock will conti
اقرأ المقال كاملاً على Yahoo Finance
المقال الأصلي منشور بواسطة Yahoo Finance في ديسمبر 30, 2025. التحليل والرؤى المقدمة من AnalystMarkets AI.